Prospera Transplant Assessment (Qualified Clients Only)

Collection

Special Instructions

Required with specimen submission:

- Patient History Form
- **Patient insurance information**

Collection Information

- Collection kit image
- Sample Collection Instruction

Collect

Whole blood must be collected in 2 Cell-Free DNA BCT tubes included the Prospera Transplant Assessment Collection kit (ARUP Supply #55552) available online through eSupply or by contacting ARUP Client Services at (800) 522-2787.

Specimen Preparation

Transport 20 mL blood in Cell-Free DNA BCT Tube (ARUP Supply #55552) available online through eSupply or contacting ARUP Client Services at (800) 522-2787.

Storage/Transport Temperature

Room temperature (8 - 37ºC)

Stability (from collection to initiation)

Room temperature, 5 days
Refrigerated, Unacceptable
Frozen, Unacceptable

Unacceptable Conditions

Refrigerated, Frozen

Remarks

Do not expose to extreme temperatures

Prospera Transplant Assessment (Qualified Clients Only)

Ordering

Ordering Recommendations

Assessment of active rejection and injury in kidney transplant recipients that are more than 14 days posttransplant. For outpatient use.

For additional information, please see Natera's Test Information

Methodology

Targeted Sequencing with SNP

Performed

Varies

Reported

5 - 7 days

Synonyms

- kidney transplant
- liquid biopsy
- cfDNA
- dd-cfdNA
- cell-free DNA
- cell free DNA
- PROSPERA

Notes (or Technical Information)

Test utilizes a single-nucleotide polymorphism (SNP)/ informatics-based approach to detect donor organ DNA in transplant recipient's blood. The dd-cfDNA fraction is determined using a proprietary algorithm that does not require prior analysis of either donor or recipient DNA. When samples do not meet the necessary quality metrics, a test result is not provided, and the clinician is advised to perform a second draw. False positives and false negatives can occur. High dd-cfDNA fraction, associated with increased risk of active rejection (AR), may require diagnostic confirmation of AR by alternative testing methods. Low dd-cfDNA fraction results do not fully exclude the diagnosis of AR nor do they exclude the possibility of other kidney injuries. Test results should always be interpreted by a clinician in the context of clinical data.

Additional Technical Information

Prospera Transplant Assessment (Qualified Clients Only)

Resulting

Reference Interval

By report

Interpretive Data

Refer to report

Lab Section

Send-Out Lab

Administrative

CPT Codes

N/A (billed by Natera)

Referral Lab

ARUP (performed at Natera)

Approvals

NY approved

Forms & Information

- Patient History Form
- Collection information
- Additional technical information

Updated

2-JUL-2020